Irritable Bowel Syndrome with Constipation Medical Services in China

Irritable Bowel Syndrome with Constipation (IBS-C) is a functional gastrointestinal disorder characterized by chronic or recurrent abdominal pain or discomfort associated with altered bowel habits—specifically, constipation-predominant symptoms—in the absence of structural, biochemical, or infectious abnormalities. According to the Rome IV criteria, diagnosis requires abdominal pain occurring on average at least one day per week in the last three months, associated with two or more of the following: improvement with defecation, onset associated with a change in stool frequency, and onset associated with a change in stool form (e.g., lumpy/hard stools). Unlike inflammatory bowel disease or colorectal cancer, IBS-C involves no mucosal inflammation, ulceration, or organic pathology; rather, it reflects dysregulation across the brain-gut-microbiota axis.

The pathogenesis of IBS-C remains multifactorial and incompletely understood. Key mechanisms include visceral hypersensitivity (heightened perception of gut stimuli), abnormal colonic motility (prolonged transit time, reduced high-amplitude propagating contractions), altered gut microbiota composition (dysbiosis), low-grade immune activation, impaired serotonin (5-HT) signaling—particularly reduced 5-HT release from enterochromaffin cells—and genetic and epigenetic susceptibility. Psychosocial factors—including stress, anxiety, depression, and early-life adversity—modulate central nervous system processing of gut signals and exacerbate symptom severity. Post-infectious triggers, dietary intolerances (e.g., FODMAPs), and bile acid malabsorption may also contribute in subsets of patients.

Epidemiologically, IBS affects approximately 10–15% of the global population, with IBS-C representing roughly 15–25% of all IBS subtypes. Prevalence is higher in women (female-to-male ratio ~2:1), peaks between ages 30–50, and shows regional variation—studies in China report community prevalence of 6–10%, with IBS-C accounting for ~20% of diagnosed cases. Risk factors include female sex, younger age (<45 years), psychological comorbidities (anxiety, depression, somatization), history of gastrointestinal infection, antibiotic exposure, sedentary lifestyle, low-fiber diet, and family history of functional GI disorders.

IBS-C significantly impairs quality of life. Patients frequently report work absenteeism, reduced productivity (presenteeism), social withdrawal, sleep disturbances, and diminished sexual function. Chronic abdominal discomfort, bloating, straining, and infrequent or incomplete evacuation lead to frustration, helplessness, and treatment dissatisfaction. Psychological burden is compounded by diagnostic delays, stigma surrounding bowel symptoms, and limited access to specialized care. Economic impact extends beyond direct medical costs to indirect losses—including lost wages and caregiver burden—making IBS-C a substantial public health concern requiring integrated biopsychosocial management.

Irritable Bowel Syndrome with Constipation (IBS-C) is a functional gastrointestinal disorder characterized by chronic abdominal discomfort or pain associated with altered bowel habits—specifically, constipation-predominant stool patterns (e.g., Bristol Stool Form Scale types 1–2), straining, sensation of incomplete evacuation, sensation of anorectal obstruction, and/or a feeling of abdominal bloating or distension—in the absence of structural, biochemical, or infectious abnormalities. The pathophysiology of IBS-C is multifactorial and not fully elucidated, but current evidence points to dysregulation across several interconnected physiological domains.

Common underlying causes include visceral hypersensitivity, where patients exhibit heightened perception of normal intestinal stimuli due to peripheral and central nervous system sensitization; abnormal colonic motility, particularly delayed transit in the proximal colon and impaired high-amplitude propagating contractions in the distal colon; and disturbances in the brain-gut-microbiota axis. Altered gut microbiota composition (dysbiosis)—including reduced microbial diversity, decreased abundance of *Bifidobacterium* and *Lactobacillus*, and increased *Ruminococcus gnavus*—has been consistently observed in IBS-C cohorts and may contribute to low-grade mucosal immune activation, impaired fermentation, and diminished short-chain fatty acid (SCFA) production, thereby affecting epithelial barrier integrity and serotonin (5-HT) signaling.

Triggers are often individualized but commonly include dietary factors such as inadequate dietary fiber intake, excessive consumption of fermentable oligo-, di-, monosaccharides and polyols (FODMAPs), lactose or fructose malabsorption, gluten sensitivity (independent of celiac disease), and insufficient fluid intake. Psychological stressors—including acute life events, chronic work-related stress, or interpersonal conflict—can acutely exacerbate symptoms via corticotropin-releasing factor (CRF)-mediated modulation of gut motility, secretion, and permeability. Other triggers include hormonal fluctuations (e.g., menstrual cycle-related progesterone surges that inhibit colonic contractility), certain medications (e.g., anticholinergics, calcium channel blockers, opioids, tricyclic antidepressants), and post-infectious states following acute gastroenteritis (though less common in IBS-C than in IBS-D).

Established risk factors encompass female sex (with a 2:1 female-to-male predominance), younger age at symptom onset (typically before age 45), history of psychological comorbidities—including generalized anxiety disorder, depression, somatization, and early-life adversity (e.g., childhood abuse or neglect)—and prior gastrointestinal infection. A history of antibiotic exposure, particularly broad-spectrum regimens, is associated with persistent dysbiosis and increased IBS-C susceptibility. Sedentary lifestyle and obesity (BMI ≥30 kg/m²) independently correlate with symptom severity and reduced response to conventional therapies.

Genetic factors play a modest but significant role. Polymorphisms in genes regulating serotonergic neurotransmission—including *HTR3E* (5-HT₃ receptor subunit), *SLC6A4* (serotonin transporter, 5-HTTLPR variant), and *TPH1* (tryptophan hydroxylase-1)—have been linked to altered colonic transit and visceral sensitivity. Variants in *GNB3* (G-protein β3 subunit), involved in intracellular signal transduction, and *TNFSF15* (tumor necrosis factor superfamily member 15), associated with mucosal immune regulation, also demonstrate replicated associations with IBS-C in genome-wide association studies (GWAS). Familial aggregation is evident, with first-degree relatives of IBS-C patients exhibiting a 2- to 3-fold increased risk, suggesting shared genetic and environmental influences.

Environmental factors include socioeconomic determinants—such as lower educational attainment and occupational stress—and geographic variables, with higher prevalence reported in urban versus rural populations, possibly reflecting differences in diet, pollution exposure, and microbiome acquisition patterns. Early-life environmental exposures—including cesarean delivery, formula feeding, and lack of household pet exposure—are associated with altered microbiome maturation and increased risk of functional GI disorders later in life. Chronic sleep disruption and circadian misalignment impair colonic motor activity and gut barrier function, further contributing to IBS-C pathogenesis. Collectively, IBS-C arises from dynamic interactions among genetic predisposition, early-life programming, microbiome ecology, neuroimmune signaling, and psychosocial context—underscoring the necessity for personalized, biopsychosocial management strategies.

Irritable Bowel Syndrome with Constipation (IBS-C) is a functional gastrointestinal disorder characterized by chronic, recurrent abdominal discomfort or pain associated with altered bowel habits—specifically constipation—without evidence of structural, biochemical, or inflammatory pathology. It falls under the Rome IV diagnostic criteria for functional bowel disorders and is managed primarily within gastroenterology (Digestive Medicine Department). Early symptoms of IBS-C often manifest insidiously and may be subtle, leading to delayed recognition. Patients commonly report a gradual onset of bloating, a sensation of incomplete evacuation after defecation, and increased straining during bowel movements—typically occurring over several months prior to formal evaluation. Abdominal distension, especially postprandially, and a subjective feeling of stool 'stuck' in the rectum are frequent early complaints. Some individuals notice heightened sensitivity to certain foods (e.g., dairy, gluten-containing products, high-FODMAP items) or stress-related exacerbations before meeting full diagnostic thresholds. Importantly, early symptoms lack red-flag features: there is no unintentional weight loss, nocturnal awakening due to pain, rectal bleeding, fever, or progressive dysphagia—these would prompt urgent investigation for organic disease.

Typical symptoms of IBS-C are defined by the Rome IV criteria: recurrent abdominal pain, on average at least one day per week in the last three months, associated with two or more of the following: (1) related to defecation; (2) associated with a change in frequency of stool; and (3) associated with a change in form (appearance) of stool. In IBS-C, stool consistency is predominantly hard or lumpy (Bristol Stool Form Scale types 1–2), with fewer than three spontaneous complete bowel movements (SCBMs) per week. Straining is reported in >25% of defecations, and a sensation of incomplete evacuation or anorectal obstruction/blockage occurs in >25% of bowel movements. Patients frequently describe abdominal discomfort rather than sharp pain—often crampy, diffuse, and variable in intensity—and it typically improves after defecation. Pain location is usually lower abdominal but may shift; it rarely localizes to a fixed point or radiates. Symptom severity fluctuates, with periods of remission and relapse influenced by dietary intake, hormonal changes (e.g., menstrual cycle), psychological stressors, and sleep disruption.

Accompanying symptoms are highly prevalent and contribute significantly to morbidity. Bloating and visible abdominal distension affect up to 90% of patients and are often disproportionate to objective findings on physical exam. Excessive flatulence, abdominal rumbling (borborygmi), and a sensation of pelvic pressure are common. Many patients experience comorbid functional disorders: chronic fatigue, fibromyalgia, tension-type headache, and temporomandibular joint disorder occur at elevated rates. Psychologically, anxiety and depression are present in approximately 40–60% of IBS-C patients—not merely reactive but likely sharing underlying pathophysiological mechanisms involving gut-brain axis dysregulation, altered serotonin signaling (particularly 5-HT4 receptor hypofunction), and visceral hypersensitivity. Sleep disturbances—including difficulty initiating or maintaining sleep—are frequent and bidirectionally linked to symptom severity. Urinary symptoms such as urgency or frequency may co-occur, reflecting shared pelvic floor dysfunction or central sensitization.

Complications of IBS-C are primarily functional and psychosocial rather than life-threatening. Chronic constipation can lead to secondary complications including hemorrhoids, anal fissures, and rectal prolapse—especially with prolonged excessive straining. Fecal impaction, though uncommon in pure IBS-C, may develop in susceptible individuals (e.g., elderly, polypharmacy users) and mimic or precipitate pseudo-obstruction. Importantly, IBS-C does not increase risk for colorectal cancer, inflammatory bowel disease, or other organic GI malignancies. However, persistent symptoms may result in significant healthcare utilization, work absenteeism, reduced quality of life (measured by validated tools such as IBS-QOL), and iatrogenic harm from unnecessary investigations or inappropriate laxative overuse (e.g., stimulant laxative dependence, electrolyte imbalances, melanosis coli). Psychological complications include health anxiety, catastrophizing, and avoidance behaviors (e.g., limiting social activities, travel, or dining out), which further entrench symptom perception and disability.

Diagnosis of IBS-C remains clinical and relies on positive symptom criteria supplemented by exclusion of alarm features. Initial evaluation includes comprehensive history (duration, pattern, triggers, family history, medication review—including opioids, anticholinergics, calcium channel blockers), physical examination (to assess for abdominal tenderness, masses, organomegaly, digital rectal exam for tone, sphincter function, and presence of fecal loading), and targeted laboratory testing: complete blood count, C-reactive protein or erythrocyte sedimentation rate, celiac serology (tissue transglutaminase IgA), and thyroid-stimulating hormone. Colonoscopy is not routinely indicated in patients under age 50 without red flags; however, it is recommended for those ≥50 years (per screening guidelines) or with new-onset symptoms after age 50, unexplained iron deficiency anemia, or persistent abnormal findings. Anorectal physiology testing (e.g., balloon expulsion test, anorectal manometry) may be considered in refractory cases to identify dyssynergic defecation—a treatable contributor to constipation that overlaps with but is distinct from IBS-C. Breath testing for small intestinal bacterial overgrowth (SIBO) or lactose intolerance is not routinely recommended unless clinically suggestive, given low specificity and high false-positive rates.

Differential diagnosis is critical to avoid misclassification. Organic causes of constipation-predominant symptoms must be systematically excluded. Hypothyroidism, hypercalcemia, diabetes mellitus (with autonomic neuropathy), Parkinson’s disease, and spinal cord lesions can cause slow-transit constipation. Medication-induced constipation (e.g., opioids, tricyclic antidepressants, iron supplements) is extremely common and often underrecognized. Structural etiologies include colonic inertia, Hirschsprung’s disease (rare in adults but possible in young-onset severe constipation), colorectal neoplasms, strictures, or diverticular disease causing obstructive symptoms. Inflammatory conditions such as microscopic colitis or quiescent Crohn’s disease may present with constipation-dominant patterns. Functional constipation (FC), per Rome IV, differs from IBS-C in that abdominal pain is absent or insufficient to meet criteria—thus, FC lacks the pain component central to IBS diagnosis. Other functional disorders like functional bloating or functional anorectal pain may overlap but lack the full constellation. Finally, psychiatric conditions such as major depressive disorder or somatic symptom disorder require careful assessment, as they may coexist or masquerade as IBS-C—but diagnosis of IBS-C should never be made solely on exclusion of psychiatric illness. A thorough, empathetic, and evidence-based approach ensures accurate classification, appropriate therapeutic targeting, and preservation of patient trust.

Irritable Bowel Syndrome with Constipation (IBS-C) is a functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits—specifically, constipation-predominant symptoms including straining, lumpy or hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction/blockage, and a feeling of abdominal bloating or distension—in the absence of structural or biochemical abnormalities. Diagnosis follows Rome IV criteria and requires exclusion of organic disease via appropriate clinical evaluation, including targeted laboratory testing (e.g., complete blood count, celiac serology, thyroid-stimulating hormone), and, when indicated, colonoscopy in patients with alarm features (e.g., onset after age 50, unexplained weight loss, rectal bleeding, family history of colorectal cancer or inflammatory bowel disease).

Conservative treatment forms the cornerstone of IBS-C management and should be initiated first-line. Dietary modification is evidence-based and individualized: increasing soluble fiber intake (e.g., psyllium, oats, flaxseed) to 10–12 g/day improves stool frequency and consistency without exacerbating gas or bloating—unlike insoluble fiber (e.g., wheat bran), which may worsen symptoms. A low-FODMAP diet, implemented under guidance of a registered dietitian, demonstrates moderate efficacy in reducing global IBS symptoms, particularly bloating and abdominal pain, in approximately 50–75% of responders; however, it is not intended for long-term use and must be followed by structured reintroduction and personalization to avoid nutritional deficiencies and microbiome dysbiosis. Adequate hydration (1.5–2 L/day) and regular physical activity (≥150 minutes/week of moderate-intensity exercise) are strongly recommended to support colonic motility and autonomic regulation. Cognitive behavioral therapy (CBT), gut-directed hypnotherapy, and mindfulness-based stress reduction have robust evidence for improving symptom severity, quality of life, and central pain processing in IBS-C, particularly in patients with comorbid anxiety or depression. Sleep hygiene optimization and smoking cessation are also integral components of nonpharmacologic care.

Pharmacotherapy is indicated when conservative measures fail to achieve adequate symptom control after 4–6 weeks. First-line agents include osmotic laxatives such as polyethylene glycol (PEG) 3350 (17 g daily), which increases intraluminal water content and softens stool without systemic absorption or dependency risk. Second-line options include selective serotonin type 4 (5-HT4) receptor agonists: prucalopride (2 mg daily in adults <65 years; 1 mg if ≥65 years) enhances colonic transit and improves spontaneous bowel movements (SBMs) and complete SBMs (CSBMs) in randomized trials. Guanylate cyclase-C (GC-C) agonists represent a major therapeutic advance: linaclotide (290 mcg daily) and plecanatide (3 mg daily) stimulate intestinal fluid secretion and reduce visceral hypersensitivity via local activation of GC-C receptors on enterocytes—both demonstrate statistically significant improvements in abdominal pain and CSBMs versus placebo over 12 weeks, with sustained efficacy in long-term extension studies. Tenapanor, a minimally absorbed NHE3 inhibitor, reduces sodium absorption in the gut, thereby increasing luminal water and accelerating transit while concurrently decreasing abdominal pain through modulation of gut-brain signaling. For refractory cases with prominent pain, low-dose tricyclic antidepressants (e.g., amitriptyline 10–25 mg at bedtime) may be considered off-label for their neuromodulatory effects on visceral afferents, though anticholinergic side effects require caution. Lubiprostone (8 mcg twice daily), a chloride channel activator, remains an option but is less favored due to higher rates of nausea compared with newer agents.

Surgical treatment has no role in the routine management of IBS-C. Surgery is contraindicated because IBS-C is a functional—not structural—disorder; colectomy, ileostomy, or other resections do not address the underlying pathophysiology (i.e., visceral hypersensitivity, altered gut-brain axis signaling, dysbiosis, or abnormal motility patterns) and carry substantial morbidity, mortality, and risk of worsening symptoms. Surgical intervention should only be contemplated in exceedingly rare cases where diagnostic uncertainty persists despite exhaustive evaluation and alternative diagnoses (e.g., chronic intestinal pseudo-obstruction, severe outlet obstruction from anatomical defects) are confirmed—and even then, surgery targets the specific organic pathology, not IBS-C itself.

Treatment advantages in China reflect integration of evidence-based Western medicine with standardized Traditional Chinese Medicine (TCM) modalities within tiered healthcare delivery. Major academic medical centers (e.g., Peking Union Medical College Hospital, Zhongshan Hospital Fudan University) offer multidisciplinary IBS clinics combining gastroenterology, nutrition, psychology, and TCM specialists. Standardized TCM pattern differentiation—commonly identifying 'Liver Qi Stagnation with Spleen Deficiency' or 'Intestinal Dryness due to Yin Deficiency'—guides individualized herbal formulas (e.g., modified Xiao Yao San or Run Chang Wan), acupuncture (targeting ST25, SP15, CV6, and LI4), and moxibustion, all supported by growing RCT evidence for symptom reduction and improved bowel function. China’s national health system enables rapid access to advanced diagnostics (high-resolution anorectal manometry, wireless motility capsules) and novel therapeutics—including early adoption of linaclotide and prucalopride—often at lower cost than in Western markets. Furthermore, digital health platforms (e.g., WeDoctor, Ping An Good Doctor) facilitate remote symptom tracking, dietary coaching, and CBT delivery, enhancing adherence and continuity of care.

Recovery advice emphasizes long-term self-management and realistic expectations. Patients should understand that IBS-C is a chronic, relapsing condition—not curable but highly manageable. Symptom diaries (recording food, stress, bowel movements, pain) help identify personalized triggers. Avoidance of unnecessary antibiotics, proton pump inhibitors, and opioid analgesics—known to disrupt microbiota and slow transit—is critical. Regular follow-up every 3–6 months allows for timely adjustment of therapy and screening for emerging comorbidities (e.g., depression, fibromyalgia). Patients are encouraged to engage in peer support networks and evidence-based patient education resources (e.g., International Foundation for Gastrointestinal Disorders). Finally, vaccination against influenza and pneumococcus is advised, given the increased prevalence of immune dysregulation in IBS populations. With comprehensive, patient-centered care, most individuals with IBS-C achieve meaningful improvement in symptom burden, functional status, and quality of life.